Irbesartan/Hydrochlorothiazide to Control Elevated Blood Pressure to Target in Moderate to Severe Hypertensive Patients

Inclusion Criteria: * Essential hypertensive patients * Moderate to severe Patients with uncontrolled blood pressure (systolic blood pressure ≥160mmHg, diastolic blood pressure ≥100mmHg for untreated, systolic blood pressure ≥150mmHg, diastolic blood pressure ≥95mmHg for treated on monotherapy). * Patients are willing to discontinue previous antihypertensive medicine Exclusion Criteria: * Pregnant or lactating women, or women of child bearing potential without contraceptive method. * Hypersensitivity to any component of the products or other sulfonamide derived substances. * Secondary hypertension. * Severe renal impairment (Creatinine Clearance ≤30ml/min) * Severe hepatic impairment, biliary cirrhosis and cholestasis. * Refractory hypokalemia, hypercalcaemia. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.